CV Sciences (CVSI) EBT Growth (3y) (2014 - 2026)
CV Sciences (CVSI) EBT Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 21.00% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.19% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 3.60% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -29.91% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 10.08% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 39.40% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | CV Sciences | 3.90 Mn | 3.63 Mn | 1.45 Mn | 15.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.69% |
| Mar 31, 2026 | -28.32% |
| Dec 31, 2025 | 27.42% |
| Sep 30, 2025 | 28.18% |
| Jun 30, 2025 | 53.82% |
| Mar 31, 2025 | 63.60% |
| Dec 31, 2024 | 62.32% |
| Sep 30, 2024 | -125.06% |
| Jun 30, 2024 | 45.05% |
| Mar 31, 2024 | 41.63% |
| Dec 31, 2023 | 54.74% |
| Sep 30, 2023 | 47.88% |
| Jun 30, 2023 | 34.92% |
| Mar 31, 2023 | 45.41% |
| Dec 31, 2022 | 31.44% |
| Sep 30, 2022 | 16.42% |
| Jun 30, 2022 | -60.21% |
| Mar 31, 2022 | 39.14% |
| Dec 31, 2021 | -73.82% |
| Sep 30, 2021 | -26.23% |